WHO Guideline Group To Review Recommendations For Depo-Provera For Use By Women At Risk Of HIV

The BMJ: Depo-Provera: WHO set to review guidance on use by women at high HIV risk
“A World Health Organization guideline development group will convene next week (29-31 July) to review recommendations for the use of contraceptive methods by women at high risk of contracting HIV. The group will review the status of the three monthly injectable contraceptive Depo-Provera, using new evidence from a randomized clinical trial published in The Lancet last month…” (Iacobucci, 7/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.